WT1 and acute myeloid leukemia: Of the 14 samples we assessed, WT1-CTLs from the 3 donors (Hem07, Hem14, and Hem15) led to AML cell death in 12/14 samples, with ≥20% cytotoxicity (≤80% viability post-CTL treatment) used as a cutoff for defining susceptibility to WT1-CTLs (Supplementary Table 1, Supplementary Fig. 6).